(Q42625923)

4 November 2017

title

Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients (English)

1 reference

4 November 2017

1 reference

9

Toshihiko Doi

1 reference

4 November 2017

19

Atsushi Ohtsu

1 reference

4 November 2017

7

Narikazu Boku

1 reference

4 November 2017

Tatsuo Kanda

1

1 reference

4 November 2017

Toshirou Nishida

2

1 reference

4 November 2017

Norihito Wada

3

1 reference

4 November 2017

Osamu Kobayashi

4

1 reference

4 November 2017

Masakazu Yamamoto

5

1 reference

4 November 2017

Akira Sawaki

6

1 reference

4 November 2017

Masato Koseki

8

1 reference

4 November 2017

Yasushi Toh

10

1 reference

4 November 2017

Yoshihiro Kakeji

11

1 reference

4 November 2017

Toshiro Sugiyama

12

1 reference

4 November 2017

Yoshito Komatsu

13

1 reference

4 November 2017

Shojiro Kikuchi

14

1 reference

4 November 2017

Kyoji Ogoshi

15

1 reference

4 November 2017

Hitoshi Katai

16

1 reference

4 November 2017

Kazuhito Miyachi

17

1 reference

4 November 2017

Seiichi Hirota

18

1 reference

4 November 2017

publication date

23 November 2011

1 reference

International Journal of Clinical Oncology

4 November 2017

published in

1 reference

4 November 2017

volume

18

1 reference

4 November 2017

issue

1

1 reference

4 November 2017

page(s)

38-45

1 reference

https://scigraph.springernature.com/pub.10.1007/s10147-011-0339-7

4 November 2017

exact match

0 references

cites work

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0339-7

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0339-7

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0339-7

NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0339-7

A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0339-7

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0339-7

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0339-7

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0339-7

Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0339-7

Gastrointestinal stromal tumors: pathology and prognosis at different sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0339-7

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0339-7

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0339-7

An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0339-7

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0339-7

Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0339-7

Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0339-7

Gastrointestinal stromal tumor (GIST) and imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0339-7

Diagnosis of gastrointestinal stromal tumors: A consensus approach

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22105894

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10147-011-0339-7

1 reference

Dimensions Publication ID

4 November 2017

1020523400

0 references

1 reference